678 completed, 167 terminated, 115 recruiting, 88 unknown. 603 Phase 2, 518 Phase 1, 86 Phase 3, 70 Not applicable, 15 Early Phase 1.
Follow Lymphoma, Mantle-Cell: new trials by email Literature Review of Lymphoma, Mantle-Cell trials Research Report on Lymphoma, Mantle-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | TransThera Sciences (Nanjing), Inc. | 188 | 2026-10-10 | 2026-10-02 |
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 280 | 2026-10-01 | 2026-08-25 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2026-09-29 | 2026-10-14 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Miltenyi Biomedicine GmbH | 52 | 2026-09-01 | 2026-05-06 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 40 | 2026-08-24 | 2026-10-14 |
| Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia | Not yet recruiting | Tina Baykaner | 500 | 2026-08-01 | 2026-07-17 | |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-07-31 | 2026-08-17 |
| Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) Orelabrutinib, Obinutuzumab, Venetoclax - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 39 | 2026-07-15 | 2026-07-22 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 40 | 2026-07-10 | 2026-07-13 |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy Biospecimen Collection, Computed Tomography, Glofitamab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-07-08 | 2026-09-09 |
Showing 20 of 1210. Sign in to see all of them.
Lymphoma, Follicular (751) · Lymphoma, Large B-Cell, Diffuse (704) · Leukemia, Lymphocytic, Chronic, B-Cell (668) · Lymphoma, B-Cell, Marginal Zone (624) · Lymphoma, Non-Hodgkin (617) · Burkitt Lymphoma (507) · Lymphoma (488) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (482) · Lymphoma, Large-Cell, Immunoblastic (437) · Hodgkin Disease (384) · Waldenstrom Macroglobulinemia (313) · Multiple Myeloma (284) · Lymphoma, T-Cell, Cutaneous (261) · Leukemia, Myeloid, Acute (251)
Hemic and Lymphatic Diseases (1210) · Neoplasms by Histologic Type (1206) · Immunoproliferative Disorders (1205) · Lymphatic Diseases (1205) · Immune System Diseases (1204) · Lymphoproliferative Disorders (1170) · Neoplasms (1141) · Hematologic Diseases (752) · Lymphoma, B-Cell (736) · Pathologic Processes (734) · Pathological Conditions, Signs and Symptoms (734) · Disease Attributes (729) · Lymphoma (722) · Leukemia, Lymphoid (712) · Chronic Disease (679)
Rituximab (229) · Cyclophosphamide (204) · fludarabine phosphate (108) · Peripheral Blood Stem Cell Transplantation (103) · Filgrastim (87) · Etoposide (76) · Cytarabine (71) · ibrutinib (68) · Mycophenolic Acid (67) · Bortezomib (66) · Cyclosporine (63) · Whole-Body Irradiation (63) · Lenalidomide (60) · Melphalan (59) · Bendamustine Hydrochloride (58)
National Cancer Institute (NCI) (100) · Fred Hutchinson Cancer Center (70) · M.D. Anderson Cancer Center (47) · City of Hope Medical Center (41) · Memorial Sloan Kettering Cancer Center (32) · Masonic Cancer Center, University of Minnesota (26) · Case Comprehensive Cancer Center (24) · Mayo Clinic (22) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · Alliance for Clinical Trials in Oncology (16) · Roswell Park Cancer Institute (15) · Barbara Ann Karmanos Cancer Institute (13) · Jonsson Comprehensive Cancer Center (13) · National Institutes of Health Clinical Center (CC) (13) · University of Nebraska (13)
United States (903) · China (94) · Italy (82) · France (81) · Germany (74) · United Kingdom (63) · Spain (56) · Canada (55) · Australia (47) · Poland (39) · South Korea (35) · Belgium (32) · Japan (29) · Israel (24) · Switzerland (24)
Ajay Gopal (10) · Brenda Sandmaier (8) · Julie M Vose, MD (7) · David Maloney (6) · Christos E. Emmanouilides, MD (5) · Claudio G. Brunstein, MD, PhD (5) · Roger Strair, MD, PhD (5)
PMID 34515338, PMID 32499241, PMID 34398557, PMID 17242396, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20032498, PMID 22002018, PMID 22337718, PMID 23834234, PMID 24591201, PMID 24687837, PMID 25381051, PMID 27118452, PMID 30782611, PMID 32126141, PMID 32242358, PMID 32888407, PMID 33735476, PMID 34780125, PMID 34797699, PMID 36375120, PMID 36485104, PMID 38669626, PMID 10552943, PMID 10673703, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 12525530, PMID 12620412, PMID 12735303, PMID 12907446, PMID 1403051, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15107815, PMID 15459300, PMID 15466923, PMID 15570084, PMID 15598978, PMID 15817673, PMID 16030029, PMID 16061911, PMID 16116429, PMID 16123218, PMID 16135477
P30CA033572 (32), P30CA015704 (26), P30CA043703 (20), P30CA015083 (19), P30CA006973 (12), P30CA022453 (12), U10CA032102 (11), 2023 (10), P30CA016672 (10), P30CA036727 (10), 2015 (9), P30CA072720 (9), U01CA076576 (9), P01CA018029 (8), U10CA031946 (8)